Archives
-
InstaBlue Protein Stain Solution Protocol
2026-10-01
InstaBlue Protein Stain Solution is a ready-to-use Coomassie reagent for rapid visualization of protein bands in polyacrylamide gels without fixation, washing, or destaining. It is suited to routine protein electrophoresis analysis and workflows that may proceed to mass spectrometry, but it should not replace validated fixation-based or post-translational-modification-specific staining methods.
-
Hoechst 33258 for pH-Linked DNA Assays
2026-10-01
Hoechst 33258 is a bis-benzimide DNA stain that anchors nuclear measurements in tumor pH-disruption studies. This guide explains how to combine its live-cell fluorescence with independent lactate, pH, and treatment-response readouts without mistaking DNA signal for a direct pH measurement.
-
Chronic Cabozantinib Signaling Adaptation in RCC
2026-09-30
This study uses quantitative phosphoproteomics to show that acute and chronic Cabozantinib exposure produce distinct remodeling of renal cell carcinoma signaling networks. Persistent suppression of MET activation-loop phosphorylation coexists with chronic enrichment of adhesion- and MAPK/AP-1-associated programs, providing a framework for studying adaptive motility without assuming restored MET activity.
-
FLOT1–FOSL2–EphA2 Signaling in Alzheimer’s Disease
2026-09-30
A 2026 Neuropharmacology study identifies a FLOT1–FOSL2–EphA2 regulatory axis that promotes pro-inflammatory microglial polarization through p38/MAPK signaling in an APP/PS1 model. FLOT1 silencing reduced neuroinflammatory responses and improved spatial memory, providing a mechanistic framework for studying microglial state transitions in Alzheimer’s disease.
-
Axitinib (AG 013736): From Target to Translation
2026-09-29
A mechanistic and strategic guide to using Axitinib (AG 013736) for VEGF signaling pathway modulation, angiogenesis inhibition assays, and tumor growth inhibition in xenograft models. The article connects target engagement with more rigorous in vitro response metrics and translational decision-making.
-
Live-Dead Cell Staining Kit for 3D Tumors
2026-09-29
Use dual-fluorescent viability readouts to distinguish membrane-intact and membrane-compromised cells in 2D cultures, flow cytometry, and dense 3D tumor constructs. The workflow is especially useful for testing whether high-cell-density glioblastoma models preserve viability and drug-response differences that simpler cultures may miss.
-
Angiotensin III: RAAS Assay Workflows
2026-09-28
Build reproducible RAAS, aldosterone, receptor-signaling, and emerging spike–receptor binding assays with Angiotensin III (human, mouse). The workflow emphasizes sequence-defined peptide handling, matched controls, dose-response design, and clear separation between established cardiovascular applications and exploratory antiviral studies.
-
D-Mannitol: Research Workflow and Handling Guide
2026-09-28
D-Mannitol is a water-soluble biochemical reagent for controlled osmotic regulation research and experiments examining renal function or diuretic mechanisms. Use it in research workflows, not as a substitute for a validated clinical formulation, and prepare solutions for near-term use because long-term solution storage is not recommended.
-
A Transient State in Adenine Riboswitch Binding
2026-09-27
Wu and colleagues used position-selective RNA labeling and stopped-flow fluorescence to follow ligand-triggered changes in the full-length adenine riboswitch. Their results identify an early P1 response and a transient unwound-P1 conformation, showing why ligand recognition is better understood as a sequence of structural events than as a simple apo-to-holo switch.
-
Bioprinted Hypoxia in Glioblastoma Models
2026-09-26
A digital light processing bioprinting strategy uses cell density in GelMA to create a reproducible, hypoxia-associated glioblastoma model without relying solely on externally imposed oxygen deprivation or chemical HIF stabilization. The reported HIF-1α enrichment and temozolomide resistance support using cell-density-controlled constructs to study tumor adaptation and drug response, while highlighting the need to pair viability measures with hypoxia-specific readouts.
-
CSF1–IFN-β Crosstalk in Spinal Cord Repair
2026-09-25
A focal spinal cord injury study identifies reciprocal signaling between lesion-border astrocytes and microglia: astrocytic CSF1 supports microglial proliferation, while microglial IFN-β promotes astrocyte survival and border formation. Cell-specific perturbations connect this communication to wound closure and motor recovery, framing glial coordination—not either cell type alone—as a contributor to repair.
-
Electroporation for CRISPR Editing in Mouse Zygotes
2026-09-25
Hashimoto and Takemoto optimized electroporation to deliver Cas9 mRNA and guide RNA into mouse zygotes while leaving the zona pellucida intact. Their work demonstrates a scalable alternative to embryo microinjection for CRISPR/Cas9 editing, including gene disruption and ssODN-mediated knock-in, while showing that RNA uptake must be balanced against embryo survival.
-
Measuring Cancer Drug Response Beyond Viability
2026-09-24
Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central finding—that drugs can combine growth inhibition and cell killing in different proportions and on different timelines—supports using complementary measurements when interpreting in vitro experiments.
-
CUDC-907: Dual PI3K and HDAC Inhibitor Guide
2026-09-24
CUDC-907 is a dual PI3K and HDAC inhibitor for controlled cell-based studies of signaling, histone acetylation, cell-cycle progression, and apoptosis. This guide focuses on practical in vitro workflows; the compound is for scientific research only and is not intended for diagnostic, clinical, or therapeutic use.
-
Pertussis Toxin as a Gi/o Probe in DOM Models
2026-09-23
Pertussis toxin offers a way to test how Gi/o signaling shapes DOM-induced behavior, beyond its established use in immunology. This article interprets a 2024 mouse study to show why head-twitch and locomotor outcomes require separate mechanistic analysis—and where the toxin’s conclusions stop.